Glenmark Pharmaceuticals is the first
Indian company to commercially launch
Favipiravir with the brand name FabiFlu
for treating mild to moderate patients
suffering from COVID-19.
The company launched this product
In Indian Market today as, The Drug
Controller General of India (DCGI) has
given manufacturing and marketing
approval. The price of the pack of
34 tablets is Rs.3500 and Rs. 103
per tablet. The Pharma Company Glenmark
has done a clinical trial on 90 mild and
60 moderate COVID-19 patients across 11
sites in India. The Drug efficacy
is over 80 % in the treatment of Covid-19
both mild and moderate patients.
Glenn Saldanha, Chairman and Managing
Director, Glenmark Pharmaceuticals, said
" Our Company will work with the medical
and Government community to make it
accessible quickly to patients across
the country".
No comments:
Post a Comment